Raymond James Downgrades FIGS to Outperform, Lowers Price Target to $8
Raymond James analyst Rick Paterson downgrades FIGS (NYSE:FIGS) from Strong Buy to Outperform and lowers the price target from $12 to $8.
B. Riley Securities Downgrades IN8bio to Neutral, Lowers Price Target to $3
B. Riley Securities analyst Kalpit Patel downgrades IN8bio (NASDAQ:INAB) from Buy to Neutral and lowers the price target from $9 to $3.
Dawson James Downgrades BioCardia to Neutral
Dawson James analyst Jason Kolbert downgrades BioCardia (NASDAQ:BCDA) from Buy to Neutral.
Raymond James Downgrades Jounce Therapeutics to Outperform, Lowers Price Target to $3
Raymond James analyst Steven Seedhouse downgrades Jounce Therapeutics (NASDAQ:JNCE) from Strong Buy to Outperform and lowers the price target from $16 to $3.
Jefferies Downgrades Outbrain to Hold, Lowers Price Target to $4
Jefferies analyst Andrew Uerkwitz downgrades Outbrain (NASDAQ:OB) from Buy to Hold and lowers the price target from $6.5 to $4.
JP Morgan Downgrades First Quantum Minerals to Underweight, Lowers Price Target to C$26
JP Morgan analyst Dominic O'Kane downgrades First Quantum Minerals (TSX:FM) from Overweight to Underweight and lowers the price target from C$30 to C$26.
JP Morgan Downgrades Nu Holdings to Underweight
JP Morgan analyst Domingos Falavina downgrades Nu Holdings (NYSE:NU) from Neutral to Underweight.
JP Morgan Downgrades Lundin Mining to Neutral, Lowers Price Target to C$9.2
JP Morgan analyst Patrick Jones downgrades Lundin Mining (TSX:LUN) from Overweight to Neutral and lowers the price target from C$10.6 to C$9.2.
Benchmark Downgrades Emergent BioSolutions to Hold
Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.
BMO Capital Downgrades ECN Capital to Market Perform, Lowers Price Target to C$4
BMO Capital analyst Tom MacKinnon downgrades ECN Capital (TSX:ECN) from Outperform to Market Perform and lowers the price target from C$6 to C$4.